A subset analysis of the 756 (92%) patients with quantifiable tumor PD-L1 expression showed a significantly higher OS for patients treated with nivolumab, regardless of baseline factors, PD-L1 status, and number of prior therapies (33). This evidence concerns the gene CD274 and neoplasm.